UFP Technologies Q2 sales rise

UFP Technologies

04/08/2025 21:37

Overview

UFP Technologies Q2 sales rise 37%, largely in line with analyst expectations, per LSEG data

Adjusted EPS for Q2 beats analyst expectations, growing 27% yr/yr

Company completed two acquisitions, expanding capabilities in medical device market

Outlook

Company expects Q3 to be the low point of labor inefficiencies

UFP anticipates gradual improvement in labor efficiency from Q4

Company sees growth safe patient handling and robotic-assisted surgery markets

UFP expects further growth from new and acquired operations

Result Drivers

ACQUISITIONS - Sales growth driven by 2024 acquisitions and organic growth of 5%, per CEO R. Jeffrey Bailly

MEDTECH SALES - MedTech business sales increased 46%, while Advanced Components sales declined 20%

LABOR COSTS - Incremental labor costs at AJR facility impacted gross margins

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Meet
$151.18 mln
$151.60 mln (4 Analysts)
Q2 Adjusted EPS
Beat
$2.5
$2.1 (4 Analysts)
Q2 EPS
$2.23
Q2 Net Income
$17.18 mln
Q2 Gross Profit
$43.54 mln
Q2 Operating Income
$24.33 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for UFP Technologies Inc is $311.00, about 27.1% above its August 1 closing price of $226.57

The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 23 three months ago

Press Release: ID:nGNXDt3dt

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)